Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 1,466 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Infection Control Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

Lyme Disease Prevention Program

NCT00000432
View directory record Official record
Conditions
Lyme Disease, Tick-Borne Diseases
Interventions
Education about disease prevention
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
Not listed
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2001
U.S. locations
1
States / cities
Hyannis, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 24, 2013 · Synced Oct 27, 2026, 1:03 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis

NCT02517619
View directory record Official record
Conditions
Anterior Uveitis
Interventions
Dexamethasone Phosphate Ophthalmic Solution, Prednisolone Acetate Ophthalmic (1%)
Drug
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 85 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 27, 2026, 1:03 PM EDT
Terminated Phase 3 Interventional

ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

NCT06418711
View directory record Official record
Conditions
MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
Interventions
Clofazimine Inhalation Suspension, Placebo
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 85 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
54
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 27, 2026, 1:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of a Cranberry Beverage on Women With Recent History of Urinary Tract Infections

NCT01776021
View directory record Official record
Conditions
Urinary Tract Infections, Infection, Urologic Diseases
Interventions
cranberry juice, placebo beverage
Other
Lead sponsor
Ocean Spray Cranberries, Inc.
Industry
Eligibility
20 Years to 70 Years · Female only
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
17
States / cities
Chandler, Arizona • Scottsdale, Arizona • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Oct 27, 2026, 1:03 PM EDT
Completed Phase 3 Interventional Results available

TRS4Vision - A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma

NCT05042609
View directory record Official record
Conditions
Non-infectious Anterior Uveitis, Uveitic Glaucoma
Interventions
TRS01, FDA approved steroid eye drop (masked)
Drug
Lead sponsor
Tarsier Pharma
Industry
Eligibility
0 Years to 75 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
19
States / cities
La Jolla, California • Los Angeles, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 27, 2026, 1:03 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Vitamin D for COVID-19 Trial

NCT04536298
View directory record Official record
Conditions
COVID-19
Interventions
vitamin D, Placebo
Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2,024 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 27, 2026, 1:03 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

ACE393-103 Vaccination Challenge Study

NCT00859716
View directory record Official record
Conditions
Campylobacter Infection
Interventions
ACE393, Placebo vaccine
Biological
Lead sponsor
TD Vaccines A/S
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2009 · Synced Oct 27, 2026, 1:03 PM EDT
Completed Not applicable Interventional Results available

Cost-Effectiveness Study Comparing Chlorhexidine Bathing With Active Surveillance Cultures to Prevent Methicillin-resistant Staphylococcus Aureus & Other Hospital Infections

NCT00779246
View directory record Official record
Conditions
Staphylococcal Infections
Interventions
Nasal swabs for MRSA culture, Chlorhexidine gluconate, Contact isolation
Other · Drug
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
1,518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 27, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection

NCT03982186
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
JNJ-73763989, Placebo for JNJ-73763989, JNJ-56136379, Placebo for JNJ-56136379, Nucleos(t)ide Analog (NA)
Drug
Lead sponsor
Janssen Sciences Ireland UC
Industry
Eligibility
18 Years to 65 Years
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
8
States / cities
Bakersfield, California • Los Angeles, California • San Clemente, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 27, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)

NCT03562377
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebo, Tdap vaccine, Meningococcal vaccine
Drug · Biological
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 54 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
39
States / cities
Fort Smith, Arkansas • Bakersfield, California • Beverly Hills, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 27, 2026, 1:03 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Phase 3 Open-Label Controlled Trial of Convalescent Plasma in Early COVID-19 Infection

NCT06084351
View directory record Official record
Conditions
Covid19
Interventions
Convalescent Plasma, Standard of Care
Drug · Other
Lead sponsor
Larkin Community Hospital
Other
Eligibility
40 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 27, 2026, 1:03 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

(CBDRA60) to Prevent or Reduce Symptoms of COVID-19 and Prevention of Post-Acute Sequelae of SARS-CoV-2 Infection PASC

NCT04777981
View directory record Official record
Conditions
COVID-19, SAR
Interventions
CBDRA60 supplement, Placebo
Dietary Supplement
Lead sponsor
Anewsha Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Hanover, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Oct 27, 2026, 1:03 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection

NCT04488575
View directory record Official record
Conditions
Covid19
Interventions
EDP1815, Placebo
Drug
Lead sponsor
Evelo Biosciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
New Brunswick, New Jersey • Newark, New Jersey • Edinburg, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Oct 27, 2026, 1:03 PM EDT
Terminated Not applicable Interventional Results available

A Trial to Evaluate Negative Pressure Incision Management System for Groin Wounds in Vascular Surgery Patients

NCT02399111
View directory record Official record
Conditions
Surgical Procedure, Unspecified
Interventions
Prevena Incision Management System
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Oct 27, 2026, 1:03 PM EDT
Terminated Not applicable Interventional Results available

Randomized Controlled Trial of Antibiotics in the Management of Children With Community-Acquired Abscess

NCT01498744
View directory record Official record
Conditions
Abscess Soft Tissue, Methicillin-resistant Staphylococcus Aureus (MRSA) Infection, Skin Abscess
Interventions
Oral Clindamycin
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
1 Month to 17 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Oct 27, 2026, 1:03 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert

NCT05070728
View directory record Official record
Conditions
Uveitis, Uveitis, Posterior, Uveitis, Intermediate
Interventions
Sham Injector, FAI Insert
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Oct 27, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

Povidone-Iodine Oral Rinse Study

NCT05239598
View directory record Official record
Conditions
COVID-19
Interventions
Mouth rinse
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 27, 2026, 1:03 PM EDT
Terminated Phase 2 Interventional Results available

Combination Pain Therapy in HIV Neuropathy

NCT00863057
View directory record Official record
Conditions
HIV Infections, Peripheral Neuropathy
Interventions
Duloxetine, Duloxetine placebo, Methadone, Methadone placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
San Diego, California • Torrance, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 27, 2026, 1:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects

NCT03310463
View directory record Official record
Conditions
Acinetobacter Baumannii Infection
Interventions
ETX2514SUL
Drug
Lead sponsor
Entasis Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Lakewood, Colorado • Miami, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 27, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection

NCT04335084
View directory record Official record
Conditions
COVID-19, Coronavirus Infection, Sars-CoV2, Corona Virus Infection, COVID, Coronavirus, Coronavirus-19, Coronavirus 19
Interventions
Hydroxychloroquine, Vitamin C, Vitamin D, Zinc
Drug · Dietary Supplement
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 27, 2026, 1:03 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

NCT04199689
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
9vHPV Vaccine, Placebo (Saline for Injection)
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
20 Years to 45 Years · Male only
Enrollment
6,033 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
32
States / cities
Northridge, California • Rialto, California • Simi Valley, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 27, 2026, 1:03 PM EDT
Completed Phase 2 Interventional

GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection

NCT01434498
View directory record Official record
Conditions
Chronic Genotype 1a or 1b HCV Infection
Interventions
GS-5885 tablet, GS-9451 tablet, tegobuvir capsule, ribavirin tablet, placebo matching ribavirin tablet, placebo matching tegobuvir capsule
Drug · Device
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
36
States / cities
Beverly Hills, California • Coronado, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2013 · Synced Oct 27, 2026, 1:03 PM EDT
Recruiting Not applicable Interventional

Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients

NCT05653232
View directory record Official record
Conditions
HCV
Interventions
Prophylaxis (P2W), Transmit and Treat (T&T)
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
9
States / cities
La Jolla, California • Loma Linda, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 27, 2026, 1:03 PM EDT
Recruiting Not applicable Interventional

The NOTICE Study: Neurosurgery and OrThopedIcs Communication Evaluation Study Following Lumbar Fusions

NCT04140344
View directory record Official record
Conditions
Lumbar Spine Degeneration, Lumbar Spine Instability, Lumbar Spondylosis
Interventions
Text Message Group
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 27, 2026, 1:03 PM EDT